

Page numbering of Amendment

The pages of the Sequence Listing inserted after page 3 of this Amendment are numbered from 1 to 6. The page numbering of the Amendment restarts here with page 4.

Remarks

Statements required by 37 CFR 1.821 and 1.825

The content of the paper and computer readable copies of the Sequence Listing are the same and, where applicable, contain no new matter.


In view of the foregoing, it is respectfully submitted that all of the claims in this application are allowable and such favorable action is respectfully requested.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

November 21, 2001

By



Allan H. Fried
Reg. No. 31253
Seven Penn Center, 12th Floor
1635 Market Street
Philadelphia, PA 19103-2212
(215) 567-2010
Attorneys for Applicant

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please **amend** Claim 3 to read as follows:

3 (Amended). The antibody or antibody of fragment of claim 1, wherein the GIT targeting agent is selected from the group consisting of ZElan033 (PAX2 15 mer) (SEQ ID NO:1), ZElan088 (HAX42-2 20 mer) (SEQ ID NO:2) or ZElan053 (P31 D-form 16 mer) (SEQ ID NO:3).

IN THE SPECIFICATION:

Please **replace** the 5 paragraphs at page 5, line 2 through page 5, line 17, with the following 5 paragraphs:

-- Figure 1 shows the immuno responses of three groups of 2 rabbits, each group immunized, respectively, with one of KLH conjugated ZElan033, KLH conjugated ZElan088 and KLH conjugated ZElan053, when the fourth bleed samples are tested by ELISA on their respective unconjugated peptides[;].

Figure 2 shows the cross reactivity of rabbit antisera for three groups of 2 rabbits, each group immunized, respectively, with one of KLH conjugated ZElan033, KLH conjugated ZElan088 and KLH conjugated ZElan053, when the fourth bleed samples are tested by ELISA on each of synthetic peptides HAX42.2, PAX 2 15 mer and P31-D-form[;].

Figure 3 shows the immuno-reactivity of anti-HAX42-2 antisera (fifth bleed samples) on a variety of synthetic peptides[;]. The sequence for Zelan021 is SEQ ID NO:4 in the Sequence Listing herein. The sequence for Zelan071 is SEQ ID NO: 5, that for Zelan088 is SEQ ID NO:2, and that for Unconj. Antigen is SEQ ID NO:6.

Figure 4 shows the immuno-reactivity of anti-PAX2 antisera (fifth bleed samples) on a variety of synthetic peptides[;]. The sequence for Zelan018 is SEQ ID NO:7 in the Sequence Listing herein. The sequence for Zelan104 is SEQ ID NO: 8, that for Unconj.Ag is SEQ ID NO:1, and that for Zelan103A is SEQ ID NO:9.

Figure 5 shows the immuno-reactivity of anti-P31 D-form antisera (fifth bleed samples) on a variety of synthetic peptides. The sequence for Zelan024 is SEQ ID NO:10 in the Sequence Listing herein. The sequence for Unconj.Ag is SEQ ID NO: 3, that for Zelan054 is SEQ ID NO:11, and that for ZELan145 is SEQ ID NO:12.--

Please **replace** Table 1, page 8 with the following Table 1:


Table 1

Name	Sequence	N° of AMINO ACIDS
ZElan033	K(dns)-TNAKHSSHNRRTTRTR (SEQ ID NO:1)	PAX2 15 mer
ZElan088	K(dns)-SDNAKEPGDYNC CGNGNSTG (SEQ ID NO:2)	HAX-42-2 20 mer
ZElan053	K(dns) - TrKSSrSNPrGrrHPG (SEQ ID NO:3)	P31 D form 16 mer

A

CERTIFICATE OF MAILING

I hereby certify that the foregoing AMENDMENT, a diskette with a Computer-readable version of the Sequence Listing, and a Transmittal Letter re Application Serial No. 09/443,780 are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, Attn: Box Non-Fee Amendment, Washington, D.C. 20231 on this 21st day of November, 2001.



Allan H. Fried
Reg. No. 31,253